Traditionally, the poor outcome for patients with malignant brain tumours led to therapeutic nihilism. In turn, this resulted in lack of interest in neurosurgical oncology subspecialisation, and less than ideal patient pathways. One problem of concern was the low rate of tumour resection.
Problem
Until about 7 years ago, the poor outcome for patients with malignant brain tumours, predominantly glioblastoma (GBM), meant that therapeutic nihilism pervaded the management of brain tumour patients in the United Kingdom. Radical resection of tumours was inevitably followed by recurrence within the resection bed, despite post-operative adjuvant therapy. This lead to generations of surgeons questioning the role of glioma resection (1) . As a result, the surgical management of brain tumours was considered part of general neurosurgery and subspecialised services for managing these patients were poorly developed.
Cambridge was no different from the rest of the United Kingdom.
Patients were admitted to the neurosurgical unit as an emergency under the care of the on-call consultant who then decided on their management. This made treatment variable and dependent on the day the patient presented. Patients were often kept in the referring hospital until operating slots were available, and were therefore kept for a long time as inpatients. They were often transferred for neurosurgery late in the evening and only had the opportunity to discuss the operation on the morning of surgery. There was a lack of information for the patient and their family. Regularly, patients with resectable tumours were offered a tumour biopsy to make a diagnosis. They were often kept in hospital until a histological report was ready and told of their diagnosis on the ward. The lack of interest also led to lack of recruitment to clinical trials. Overall care was consultant-centred rather than patient-centred.
Background
The variation in practice and low levels of tumour resection were a concern to the clinical oncologists managing these patients. This was further highlighted by the EORTC/NCIN study in which 80% of patients had a tumour resected, setting the standard of clinical care for glioblastomas (2) .
Although common in the USA and in parts of Europe since the early 1990s, subspecialisation in neurosurgical oncology was rare in the UK. There were a couple of subspecialists, usually with an academic interest, who were virtually always single handed and could manage only some of the patients in their region. Subspecialisation in surgical oncology had been shown to improve outcome in both breast and colonic cancer (3, 4) and also in paediatric brain tumours (5) . Similar data does not exist in adult brain tumours. In fact, a single centre study from Edinburgh showed no improvement in survival in patients treated by a single-handed specialist neurosurgical oncologist (6) . 
Design
It was clear that to improve consistency of management it would be necessary to limit the number of surgeons operating on adult glioma patients. The key to this was to establish a pathway of care in which all patients were discussed pre-operatively in an MDT meeting and then directed into the surgical neuro-oncology service. An outpatient surgical neuro-oncology clinic was set up as a first point of specialist contact and to aid recruitment into research studies.
Support from oncology colleagues provided the pressure to ensure patients were managed in this way and strengthened links between neurosurgery and oncology within the Anglian Cancer Network. The changes in the process of care allowed us to better counsel patients and their families and provide them with appropriate information throughout the patient journey.
Our major concern was how other neurosurgical consultants would accept such a proposal. Most were happy to allow oncology patients to be managed in this way. A few were not and would block attempts to change practice. For that reason we set about change by 'evolution' rather than 'revolution'. We needed to demonstrate that we could provide 'added value' for patient care. The publication of the Improved Outcomes Guidelines in Brain Tumours in June 2006 provided justification and support this development (7).
Strategy
Some baseline changes were made in the previous 10 years that provided the environment required to allow the neuro-oncology service to develop. In the mid 1990's Cambridge started to move toward subspecialisation within neurosurgery -earlier than many other units. Consultants with interests in pituitary tumours, paediatric neurosurgery, skull base tumours, neurovascular surgery and complex spinal surgery were appointed and were able to clearly show the value of providing specialised services to patient care. The second change was the development of a neurooncology MDT, was prompted by the publication of the CalmanHine report (8) and NHS Cancer Plan produced in 2000 (9) . The purpose of the MDT meeting was to ensure patients were treated in multidisciplinary teams according to recognised guidelines (10). 
Results
The full results of this intervention have been described in detail previously (11) . In summary we compared the results of a six-month 
Lessons and Limitations
From our experiences we have learnt that implementing a specialist neurosurgical oncology service begins with understanding the patient care pathway. Our experience shows that very few of these patients need to be in hospital once they have had appropriate 
Conclusion
It is clear that our service and our patients have benefited from subspecialisation. This means that most glioblastoma patients are now treated by a dedicated surgical neuro-oncology service.
Demonstrating 'added value' in the form of specialist surgical techniques and volume and quality of clinical research has ensured that the service has continued to evolve. One major factor that has ensured success of this process is the excellent inter-disciplinary working relationships that have developed.
